ERBB2 and non-small cell lung carcinoma: As well, another report evinced that non-small-cell lung carcinoma (NSCLC) tumor overexpressing both EGFR and HER2 might exhibit higher sensitivity to EGFR tyrosine kinase inhibitor (TKI) compared to EGFR but not HER2 overexpressing tumors [79].